🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 79 of 857 · Phase 3 first, then by program name

  1. HYDROXYCHLOROQUINE, METHOTREXATE, Remsima 120 mg solution for injection in pre-filled pen, METHOTREXATE, IBUPROFEN, Placebo (To evaluate the efficacy and safety of CT-P13, and mainatain blindness during the study, Placebo will be administered.), PARACETAMOL, FOLIC ACID, HYDROCORTISONE

    Celltrion Healthcare Australia Pty Ltd

    Rheumatoid arthritis

    phase 3 small molecule active

    1 trial

  2. HYQVIA

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy

    phase 3 mab completed

    2 trials

  3. Hard capsules, BIIB141

    Biogen

    Friedreich’s ataxia

    phase 3 small molecule active

    1 trial

  4. HealthWise South Africa curriculum

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 3 other completed

    1 trial

  5. Hemlibra 150 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection

    Hoffmann-La Roche

    Hemophilia A

    phase 3 small molecule active

    1 trial

  6. Hemlibra 150 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection

    Hoffmann-La Roche

    Mild or moderate hemophilia A without FVIII inhibitors

    phase 3 small molecule active

    1 trial

  7. Hepatitis B adjuvanted vaccine

    GlaxoSmithKline

    Hepatitis B

    phase 3 mab completed

    1 trial

  8. Herceptin

    Hoffmann-La Roche

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  9. Herceptin 150 mg powder for concentrate for solution for infusion, DS-8201a, Perjeta 420 mg concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    Early stage HER2-positive breast cancer

    phase 3 small molecule active

    1 trial

  10. Herceptin 150 mg powder for concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Solid Malignant Tumors

    phase 3 small molecule active

    1 trial

  11. Herzuma 150 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DS-8201a, CAPECITABINE, 5-Fluorouracil Ebewe 50 mg/ml concentrat pentru soluţie injectabilă/perfuzabilă, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CAPECITABINE, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Daiichi Sankyo

    Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer

    phase 3 small molecule active

    1 trial

  12. Herzuma 420 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, Perjeta 420 mg concentrate for solution for infusion, CYCLOPHOSPHAMIDE, DS-8201a, PACLITAXEL, DOXORUBICIN, Herzuma 150 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE

    AstraZeneca AB

    Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)

    phase 3 small molecule active

    1 trial

  13. Hexaxim®

    Sanofi Pasteur

    Diphtheria

    phase 3 mab completed

    1 trial

  14. High Dose Colchicine (4.8 mg total dose)

    Takeda

    Gout

    phase 3 small molecule completed

    1 trial

  15. Home non-invasive ventilation

    United Therapeutics Europe Ltd

    Hypercapnic Respiratory Failure

    phase 3 other completed

    1 trial

  16. Hormonal Contraception

    United Therapeutics Europe Ltd

    Pregnancy

    phase 3 small molecule completed

    1 trial

  17. Hormone replacement therapy (estrogen/progestin)

    United Therapeutics Europe Ltd

    Anorexia Nervosa

    phase 3 small molecule completed

    1 trial

  18. Household-based water treatment with NADCC tablets

    United Therapeutics Europe Ltd

    Diarrhoea

    phase 3 other completed

    1 trial

  19. Houyanqing Oral Liquid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Cancinoma (NPC)

    phase 3 small molecule active

    1 trial

  20. Human Erythropoiesis Injection (CHO cell)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Kidney Failure, Chronic

    phase 3 small molecule active

    1 trial

  21. Human Insulin Inhalation Powder

    Eli Lilly and Company

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  22. Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Norovirus Infections

    phase 3 mab completed

    1 trial

  23. Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)

    Takeda

    Hemophilia A

    phase 3 small molecule completed

    1 trial

  24. Human rotavirus liquid vaccine

    GlaxoSmithKline

    Infections, Rotavirus

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources